HC Wainwright Issues Pessimistic Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Thursday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.40) per share for the quarter, down from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.43) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.32) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $1.98 EPS, FY2029 earnings at $3.08 EPS and FY2030 earnings at $3.11 EPS.

Other analysts have also issued research reports about the stock. B. Riley Financial restated a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Guggenheim reiterated a “buy” rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research cut Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. Five analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Unicycive Therapeutics has an average rating of “Hold” and a consensus target price of $18.25.

Unicycive Therapeutics Price Performance

UNCY stock opened at $5.63 on Monday. The company has a 50 day simple moving average of $5.88 and a 200 day simple moving average of $6.62. The stock has a market cap of $156.82 million, a price-to-earnings ratio of -3.22 and a beta of 1.79. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in Unicycive Therapeutics during the 2nd quarter worth approximately $248,000. Seven Fleet Capital Management LP bought a new stake in Unicycive Therapeutics during the 1st quarter worth approximately $367,000. Bank of America Corp DE grew its holdings in Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after acquiring an additional 29,378 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Unicycive Therapeutics in the 1st quarter valued at approximately $161,000. Finally, Dimensional Fund Advisors LP acquired a new position in Unicycive Therapeutics in the 1st quarter valued at approximately $940,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.